Navigation Links
Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P

Pharma company Lupin Ltd today said it has received approval from the Drugs Controller General (India) (DCGI) to conduct Phase II clinical trials for the molecule LL-42 18 (Desoside-P).//

The company received permission to continue Phase II clinical trials on the Psoriasis pure compound, LL-42 18, after DCGI found the clinical Phase I data of the molecule to be satisfactory.

Lupin informed the Bombay Stock Exchange that it intends to begin clinical trials at 5-6 centres immediately.

'We are delighted that our Phase I data has been found to be satisfactory for us to proceed with further clinical trials. We are very excited with taking the molecule forward and look forward to meeting this otherwise unmet market need,' Company Chairman Desh Bandhu Gupta said.

LL-4218, a pure molecule, is obtained from a plant source and is intended for the treatment of chronic stable plaque type psoriasis. This molecule's novel mechanism of action leads to marked psoriatic lesion improvement without any toxic effects.

The company said it also has three other new chemical entities in various stages of clinical trials.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Lupin flour may cause peanut allergy like reactions
2. Lupin Gets USFDA Approval For Quinapril Tablets
3. US Court Rules Against Lupin in Ramipril Patent Case
4. Lupin Gets USFDA Approval for Meloxicam
5. Lupin Gets Tentative Nod from FDA for Antidepressant Drug
6. SARS-Free Taiwan to Mark End Phase of Global Fight
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. FDA approves Phase 0 trial which tests experimental drugs on humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric company ... Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount Power ... customers and 2,250 RCEs at the time of acquisition. In the three years ...
(Date:2/27/2017)... , ... February 27, 2017 , ... New Jersey ranks ... among all types and genders. And the need for advanced services is growing. ... its top-rated cancer care program, in collaboration with their non-profit partners in their fight ...
(Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
(Date:2/26/2017)... VA (PRWEB) , ... February 26, 2017 , ... ODH, ... Managed Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ... with PerformCARE to use behavioral health analytics to improve Medicaid population health management. , ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... newly designed TaskMate Go. Core benefits and advantages built into the home office ... stylish, functional look and feel. Ability to gain the benefits embedded in the ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Inc. (NYSE: HYH ) today reported fourth quarter ... related key planning assumptions. Executive Summary 2016 fourth ... compared to the prior year. Net income ... net income of $15 million in the fourth quarter of ... to adjusted net income of $27 million in the prior ...
(Date:2/27/2017)... Texas , Feb. 27, 2017  International Biophysics Corporation, ... Texas , today announced a 34% revenue growth in ... 53% increase in unit sales.  This growth was fueled by ... in addition to the expansion of its global sales ... Jr., International Biophysics, CEO, "As we enter our 25 th ...
(Date:2/27/2017)... (NASDAQ: IPXL ) today announced that it plans to participate ... James and Associates, 38 th Annual Institutional Investors Conference at ... Cowen and Company 37 th Annual ... Boston, MA. Barclays Global Healthcare ... FL. Individuals may listen to the ...
Breaking Medicine Technology: